Key Points
- Pacira SVP Lauren Riker sold 6,000 shares at an average price of $36.32, worth $217,920, reducing her holdings by 8.79% to 62,284 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Viatris agreed to acquire Pacira for $36.50 per share in cash, valuing the company’s equity at approximately $1.65 billion. The deal is expected to close by the end of 2026, subject to customary conditions, effectively limiting near-term upside unless a competing bid emerges.
- Pacira recently exceeded quarterly earnings expectations, reporting $0.73 in EPS versus the $0.65 consensus and revenue of $192.4 million, up 6.2% year over year. Analysts’ consensus rating remains Hold, with a consensus price target of $33.33.
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 6,000 shares of the stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total transaction of $217,920.00. Following the transaction, the senior vice president owned 62,284 shares of the company's stock, valued at $2,262,154.88. This trade represents a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pacira BioSciences Stock Performance
Shares of NASDAQ:PCRX opened at $36.31 on Friday. The firm has a fifty day simple moving average of $25.56 and a two-hundred day simple moving average of $24.59. Pacira BioSciences, Inc. has a 52 week low of $18.80 and a 52 week high of $36.46. The company has a quick ratio of 3.94, a current ratio of 5.04 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $1.45 billion, a P/E ratio of 103.75 and a beta of 0.25.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The firm had revenue of $192.40 million for the quarter, compared to analysts' expectations of $191.06 million. During the same period in the prior year, the company earned $0.74 EPS. The business's revenue was up 6.2% compared to the same quarter last year. On average, analysts expect that Pacira BioSciences, Inc. will post 1.86 earnings per share for the current fiscal year.
Key Stories Impacting Pacira BioSciences
Here are the key news stories impacting Pacira BioSciences this week:
- Positive Sentiment: Viatris agreed to buy Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction gives shareholders a defined exit price and is expected to close by the end of 2026, subject to customary conditions. Viatris acquisition announcement
- Positive Sentiment: Viatris will add Pacira’s marketed non-opioid pain therapies, EXPAREL and ZILRETTA, along with a clinical-stage gene therapy candidate. Viatris expects the deal to expand its pain portfolio and be immediately accretive to its financial guidance metrics.
- Neutral Sentiment: RBC said a superior competing bid is unlikely, reducing the prospect of a higher offer but also lowering takeover uncertainty. The stock’s upside is therefore largely capped near the $36.50 consideration unless another bidder emerges. RBC superior bid analysis
- Neutral Sentiment: Analyst actions largely reflect the announced deal: JPMorgan upgraded PCRX to neutral, while RBC and Truist raised targets to $36.50 and maintained sector perform or hold ratings. HC Wainwright maintained neutral with a $36.50 target, and Jefferies kept hold with a $36.00 target.
- Negative Sentiment: Several shareholder-rights law firms are investigating whether Pacira’s board obtained fair value and conducted an adequate sale process. These investigations could create legal or procedural distractions, although no wrongdoing has been established. Shareholder investigation
Analysts Set New Price Targets
Several research firms have recently issued reports on PCRX. Truist Financial reaffirmed a "hold" rating and issued a $36.50 price objective (up from $31.00) on shares of Pacira BioSciences in a research note on Friday. Weiss Ratings raised Pacira BioSciences from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday. Royal Bank Of Canada raised their price target on Pacira BioSciences from $25.00 to $36.50 and gave the stock a "sector perform" rating in a research report on Friday. Zacks Research lowered shares of Pacira BioSciences from a "hold" rating to a "strong sell" rating in a research note on Monday, October 5th. Finally, Leerink Partners started coverage on shares of Pacira BioSciences in a research report on Wednesday, September 9th. They set a "market perform" rating and a $28.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $33.33.
Get Our Latest Stock Report on Pacira BioSciences
Institutional Investors Weigh In On Pacira BioSciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new position in Pacira BioSciences in the second quarter worth approximately $7,532,000. Bank of America Corp DE purchased a new stake in shares of Pacira BioSciences in the 2nd quarter worth $6,089,000. Empowered Funds LLC bought a new position in shares of Pacira BioSciences during the 2nd quarter worth $5,076,000. PDT Partners LLC purchased a new position in shares of Pacira BioSciences during the second quarter valued at $3,358,000. Finally, Man Group plc bought a new stake in shares of Pacira BioSciences in the second quarter valued at about $3,181,000. Institutional investors own 99.73% of the company's stock.
About Pacira BioSciences
(
Get Free Report)
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company's portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.
Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.
Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
